COMP <GO>
ELMD vs ABBV // FREE CASH FLOW YIELD
Electromed Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ELMD 8
— ABBV 5
▲ FREE CASH FLOW YIELD LEADER: ELMD
LAST: $27.04 (-2.31%) • MKT CAP: $229.4M
fcf-yield
4.85%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.10% | 70.20% | +7.90 | ELMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.10% | 29.00% | -4.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.8x | 33.3x | -11.50 | ELMD | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.85% | 3.47% | +1.38 | ELMD | /fcf-yield <GO> |
| Operating Margin | 15.10% | 24.60% | -9.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 11.80% | 6.90% | +4.90 | ELMD | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 8.60% | +8.40 | ELMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 17.64 | 5.33 | +12.31 | ELMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ELMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 65.1 | -16.30 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.5x | 113.1x | -87.60 | ELMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $229.4M | $513.86B | -$513.63B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELMD REV | ABBV REV | ELMD GROSS % | ABBV GROSS % | ELMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $64.0M | $61.16B | 78.1% | 70.2% | $11.1M | $17.82B |
| FY 2024 | $54.7M | $56.33B | 76.3% | 70.0% | $8.8M | $17.83B |
| FY 2023 | $48.1M | $54.32B | — | — | $1.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELMD // BETA —
ABBV // BETA 1.15